Despite relative success of therapy for Hodgkin's lymphoma (HL), novel therapeutic agents are needed for patients with refractory or relapsed disease. Recently, anti-PD1 immunotherapy or treatment with the anti-CD30 toxin conjugate brentuximab vedotin (BV) have been associated with remissions; however, the median responses of complete responses (CRs) with the latter were only 6.7 mo. To obtain curative therapy, other effective agents, based on HL biology, would have to be given in combination with BV. Hodgkin's Reed-Sternberg (HRS) cells secrete cytokines including IL-6 and -13, leading to constitutive activation of JAK/STAT signaling. In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2. These changes were enhanced when, on the basis of a matrix screen of drug combinations, ruxolitinib was combined with the Bcl-2/Bcl-xL inhibitor Navitoclax. The combination augmented expression of Bik, Puma, and Bax, and attenuated Bcl-xL expression and the phosphorylation of Bad. The use of the two-agent combination of either ruxolitinib or Navitoclax with BV or the three-agent combination strongly activated Bax and increased activities of cytochrome c and caspase-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1. Either ruxolitinib combined with Navitoclax or BV alone prolonged survival but did not cure HDLM-2 tumor-bearing mice, whereas BV combined with ruxolitinib and/or with Navitoclax resulted in a sustained, complete elimination of the HDLM-2 HL. These studies provide scientific support for a clinical trial to evaluate BV combined with ruxolitinib in select patients with HL.
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Hodgkin's lymphoma | ruxolitinib | Navitoclax | brentuximab vedotin H odgkin's lymphoma (HL) is a relatively common lymphoid neoplasm with a bimodal incidence curve involving ∼9,000 cases diagnosed annually in the United States (1) . The neoplastic cells in classical HL, termed Hodgkin's Reed-Sternberg (HRS) cells (2) , comprise only a minority of cells in the tumor mass. Such HRS express the CD30 surface antigen. Although HL has remained a largely curable disease, ∼20% of patients with relapsed and refractory disease will not be cured with currently available therapy and will require subsequent treatments (3) . HL patients whose disease relapses after autologous stem-cell transplantation are rarely cured with current treatment modalities. Treatment with anti-PD1 immunotherapy or the anti-CD30 toxin conjugate brentuximab vedotin (BV) have resulted in remissions in refractory and relapsed HL. However, the median complete response (CR) after BV therapy was only 6.7 mo. It is likely that combination therapies involving BV will be required to obtain a curative strategy. Thus, new drugs and novel treatment strategies are required, based on our understanding of HL biology and signaling pathways (4). Novel combination therapies are possible that take advantage of insights concerning the disorders of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in patients with HL. Malignant HRS cells secrete various cytokines, leading to activation of signaling pathways such as the NF-κB pathway and the JAK/STAT pathway (5, 6) . Constitutive phosphorylation of STAT1, STAT3, STAT5, and STAT6 have been found in several HL cell lines, as well as primary HRS cells (7) (8) (9) (10) . Cytokines secreted by HL cell lines and primary tumors include well-known activators of the JAK/STAT pathway IL-13 and -6 (11). JAK2 showed chromosomal gains in ∼20% of HL and in rare cases was translocated (12, 13) . JAK2 functions in HRS cells as an activator of STAT signaling and is also involved in epigenetic regulation, because it can phosphorylate histone H3 (14) . Novel JAK2 inhibitors such as AZD1480 and SB1518 have been investigated in both the preclinical and clinical settings involving HL (15, 16) . Our group has initiated a clinical trial using the FDA-approved JAK1/2 inhibitor ruxolitinib in the treatment of adult T-cell leukemia (ATL). To use such an agent for HL, we investigated ruxolitinib with other agents in both in vitro studies with HL cells and in a murine model with the HL cell line HDLM-2. Because it was clear that multielement combinations would be optimal, we performed a matrix screen of ruxolitinib drug combinations with HL cell lines and identified Navitoclax as the most effective partner.
The targets of Navitoclax, BcL-2 and BcL-xL, are the main effector molecules in the survival pathways downstream of activation of JAK/STAT signaling (17) . Inhibiting the oncogenic JAK2 signaling network by targeting JAK2 and BcL-2/BcL-xL Significance Hodgkin's lymphoma (HL) manifests activation of Janus kinase (JAK)/ signal transducer and activator of transcription (STAT) signaling pathway and CD30 expression on Reed-Sternberg cells. Additivity/synergy inhibiting effects were noted with combination treatments in vitro with HL cell line, HDLM-2, when treated with JAK 1/2 inhibitor; ruxolitinib with B-cell lymphoma 2 (Bcl-2)/B-cell lymphoma-extra large) (Bcl-xL) inhibitor, Navitoclax; or with anti-CD30 toxin conjugate, brentuximab vedotin (BV). Either ruxolitinib combined with Navitoclax or BV alone prolonged survival period but did not cure HDLM-2 tumor-bearing mice whereas BV combined with ruxolitinib and/or with Navitoclax resulted in sustained complete remissions in this model of HL. These studies provide scientific support for clinical trials to evaluate BV combined with ruxolitinib in select patients with HL.
provided an augmented therapeutic benefit in mutant JAK2-driven malignancies (17) (18) (19) . In our studies with the HDLM-2 murine model, the combination of ruxolitinib and Navitoclax attenuated progression of HL, but did not cure the disease. Therefore, we explored a third agent, BV, for further therapeutic trials.
CD30 is a transmembrane member of the TNF cell receptor superfamily that is highly expressed in HRS cells, but is highly restricted in normal cells (20) . Therefore, CD30 is considered an ideal target for monoclonal antibody therapy of HL (21) . BV is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody coupled to the antitubulin monomethyl auristatin E (MMAE). Binding of MMAE to tubulin disrupts the microtubule network, induces cell-cycle arrest, and results in apoptotic death of the CD30-expressing tumor cells (22) . Phase I and II trials demonstrated its impressive efficacy in relapsed HL and anaplastic large cell lymphoma (23) (24) (25) . In the present study, an additive/synergistic effect yielding complete depletions of HL cells was observed when BV was combined with either ruxolitinib or Navitoclax. Moreover, combination therapy of BV and ruxolitinib or Navitoclax led to complete remissions of established HDLM-2 lymphoma-bearing mice.
Results

Matrix Screening Highlights Ruxolitinib Drug Combinations that Block
Proliferation and Induce Apoptosis in Human HL Cells. Aberrant activities of JAK/STAT signaling pathways have been observed in several hematologic malignancies, including HL (26) . Western blot analysis showed that four of the six HL cell lines expressed phosphorylated STAT3, STAT5, or STAT6 (Fig. S1 ). Furthermore, there was selective 9p24.1 amplification with increased JAK2 induction in three of the six HL lines analyzed (KM-H2, L1236, and HDLM-2; Fig. S2 ). We examined the response of the six HL cell lines KM-H2, L428, U-HO1, L1236, L540, and HDLM-2 to a large collection of 1,912 approved and investigational drugs using a common cell viability assay that incorporated numerous JAK/STAT inhibitors, including ruxolitinib. The results of this single-agent viability screen are freely available at https://tripod.nih.gov/matrix-client/. Although most or all of the cell lines were inhibited by relatively nonspecific JAK inhibitors, such as Degrasyn and Merck-5, only two of the cell lines, HDLM-2 and L1236, responded to the more specific U.S. Food and Drug Administration (FDA)-approved JAK inhibitors, ruxolitinib (JAK1, 2) and tofacitinib (pan-JAK).
To improve on the antitumor activity of ruxolitinib we next sought out appropriate combinations for HL therapy. Therefore, we evaluated ruxolitinib combined with the same 1,912 therapeutic agents with the L1236 cell line using a previously described 6 × 6 dose-response matrix screening platform. Synergistic drug combinations from the 6 × 6 screen where then repeated in the L1236, L428, U-HO1, and HDLM-2 cell lines. The results of these experiments are freely available at https://tripod.nih.gov/matrix-client/. Additive/synergistic effects were demonstrated using the HDLM-2 cell line with ruxolitinib combined with inhibitors of Bcl-2/Bcl-xL, HDACs, Heat shock protein 90, PI3K, and mTOR. Previously, we have defined a strong synergistic effect for JAK inhibitors when combined with Bcl-2/Bcl-xL in ATL. Based upon these studies we chose to more deeply evaluate the combination effects of ruxolitinib and Navitoclax (ABT-263) in HL HDLM-2 cell line.
Blockade of JAK2/STATs Signal with Ruxolitinib and Inhibition of BcLxL with Navitoclax Yielded Antiproliferative Actions in Human HL Cell Lines. To determine whether ruxolitinib and Navitoclax are effective at reducing the viability of HL cells, we evaluated them on six human HL cell lines, KM-H2, L428, U-HO1, L1236, L540, and HDLM-2; one human B-cell lymphoma cell line, HT; and one human multiple myeloma cell line, L363. Cells were cultured with or without increasing concentrations of ruxolitinib or Navitoclax for 48 h and analyzed for 3 H-thymidine incorporation. Ruxolitinib inhibited proliferation of four HL cell lines-U-HO1, L1236, L540, and HDLM-2-in a concentration-dependent manner, but did not affect KM-H2, L428, and L363 lines up to the highest dose of 10 μM (Fig. 1A) . Navitoclax also inhibited the proliferation of four HL cell lines-L428, U-HO1, L1236, and HDLM-2-but did not affect the KM-H2, HT, or L363 lines up to the highest dose of 1.6 μM. Navitoclax had a modest effect on the proliferation of L540 cells (Fig. 1B) . Based upon these data, we evaluated the combination regimen of ruxolitinib with Navitoclax for its capacity to inhibit cell proliferation of U-HO1, L1236, HDLM-2, and the control HT line. Compared with a single reagent alone, HDLM-2 and L1236 lines treated with the combination regimens responded in an additive/synergistic fashion ( Fig. 1D) , with a meaningful induction of apoptosis as judged by a companion CaspaseGlo analysis (Fig. S3) . In contrast, the combination regimens did not possess significant inhibiting activity with HT and U-HO1 cell lines (Fig.  1D) or with the KM-H2 and L540 cell lines (Fig. S4 ).
Ruxolitinib Combined with Navitoclax and/or BV Enhanced the Antiproliferative Action and Induction of Apoptosis with HDLM-2 Cells.
We further investigated the combination of ruxolitinib and Navitoclax at multiple doses and their combination with the JAK inhibition-sensitive HDLM-2 cell line ( Fig. 2A) . The additive/ synergistic efficacy for the inhibition of proliferation was demonstrated again with this cell line. Unfortunately, although ruxolitinib or Navitoclax possessed antiproliferative action in vitro, these reagents alone or their combination did not prevent tumor progression in a xenograft mouse model with HDLM-2 HL (Fig. S5 ).
To identify a more effective therapeutic strategy, we applied a (Fig. 1C) . Furthermore, the combination of BV with either ruxolitinib or Navitoclax resulted in additive/synergistic cell killing, and the simultaneous application of all three drugs achieved the greatest additivity/synergy (Fig. 2B ). This additivity/synergy was reproducible with the L1236 cell line (Fig. S6 ). To better understand this antiproliferative action, we evaluated cell-cycle changes in HDLM-2 cells with different treatments as indicated by analyzing their DNA content. Previous studies indicated that BV induced G2/M-phase growth arrest and cell death through the induction of apoptosis (27) . Compared with untreated cells, cells treated with ruxolitinib, Navitoclax, or BV alone showed an increased percentage of the sub-G1 population; BV alone demonstrated an arrested G2/M population, whereas combinations with BV enhanced the arrest of G2/M population. The two combinations and the triple combination showed additive/synergistic efficacy with an enhanced induction of apoptosis (Fig. 2C) .
Combination of Ruxolitinib and Navitoclax and BV Enhanced Apoptosis in HDLM-2 Cells. To further understand the additivity/synergy mediated by the combinations in inducing apoptosis of HDLM-2 cells, we investigated the apoptotic related molecules cytochrome c and caspase-9 and -3. In response to apoptotic signals, cytochrome c can be released from mitochondria into the cytosol, which in turn activates an apoptotic program via caspase-driven cascades (28) . More specifically, the complex of Apaf 3/caspase-9 is activated with the release of cytochrome c, which leads to the downstream activation of caspase-3, -7, and -9. This process is followed by the activation of additional caspases, including caspase-1, -2, -4, -8, -10, and -13, that ultimately lead to cellular apoptosis (29, 30) . After single agent treatment, there is a modest 3-to 3.7-fold increase in cytochrome c, a fivefold to sevenfold increase with caspase-9, and a fivefold increase with caspase-3. Higher increases in these apoptotic elements were seen with twoand three-drug combinations (Fig. 3 A-C) . The double-positive population of active caspase-3/cleaved poly(ADP ribose) polymerase (PARP) cells was observed to be modestly increased (threefold to sixfold) in single agent treatment, significantly increased (7-to 13-fold) in two reagent combinations, whereas it was dramatically increased (16-fold) in the triple combination (Fig. 3D) . These results indicated that there was enhanced apoptosis mediated by the combinations of the two or three agents with HDLM-2 cells.
Blockade of JAK/STAT Signaling Pathway and Regulation of Bcl-2 Family Members Participated with Antiapoptotic and Proapoptotic
Actions and Contributed to Apoptosis of HDLM-2 Cells. Because the JAK/STAT pathway is constitutively activated in HDLM-2 cells (31), we examined how blockade of this signaling axis by ruxolitinib modified key apoptosis-related Bcl-2 family proteins. As expected, the phosphorylation status of both STAT3 and STAT6 were dramatically reduced with ruxolitinib treatment (Fig. 4A) . By directly targeting antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL, Navitoclax effectively amplifies the apoptotic response in HDLM-2 cells. To further understand the effector mechanism of the combination, Bcl-2 family members that are key elements of the apoptosis machinery were examined. Ruxolitinib, Navitoclax, and the combination of these agents triggered the cleavage of antiapoptotic protein Mcl-1, resulting in 24-and 17/19-kDa products, whereas BV had no effect on the Mcl-1 cleavage, but slightly suppressed its expression. The application of all three drugs alone or in combination did not affect Bcl-2 levels after 48-h treatment; however, ruxolitinib alone or in combination did modestly suppress Bcl-xL levels (Fig. 4A) . BH3-only members of the Bcl-2 family-which include Bim, Bmf, Bik, Bad, Bid, Puma, Noxa, and Hrk-mediate many developmentally programmed and induced cytotoxic signals (32) . The levels of proapoptotic Bim complex of Bim extralong (Bim EL ), Bim long (Bim L ), and Bim short (Bim S ) were increased with ruxolitinib treatment, but decreased after the combination of Navitoclax and BV (Fig. 4B) . Puma (33) levels increased after ruxolitinib or Navitoclax single treatment and significantly increased with their combination. Bik was expressed with the combination regimen with the greatest expression detected with the triple combination. Modest down-regulation of phospho-Bad was noted after BV treatment, whereas profound suppression was observed with the triple-combination treatment (Fig. 4 B and  C) . In response to apoptotic signals, Bax-mediated destabilization may trigger mitochondrial swelling and the release of cytochrome c into the cytosol, which could result in the acceleration of cell death. Some BH3-only proteins (specifically Bim) can directly activate Bax and/or Bad to translocate to the outer mitochondrial membrane and thereby lead to caspase activation. To evaluate the effect of the three reagents and their combinations on this process, we investigated Bax, active Bax (Fig. 4 B  and C) , and the mitochondrial membrane potential (Fig. S7) . Increased Bax and active Bax levels were noted after treatment with each drug individual with profound elevations for all BVrelated combination regimens (Fig. 4 B and C) . Mitochondrial depolarization was also noted after administration of each drug, with more profound effects noted for the drug combinations (Fig. S7) .
Cytochrome c release from mitochondria initiates a caspase cascade, which, in turn, cleaves a series of substrates including PARP. PARP is a universal marker of the apoptotic process and one of the main cleavage targets of caspase-3. The cleaved PARP was seen with both ruxolitinib and Navitoclax alone treatments and was further enhanced in the double or triple combinations (Fig. 4B) . Furthermore, previous studies demonstrated that Myc, as a major target of JAK2-mediated histone phosphorylation, was silenced after JAK2 inhibition in primary mediastinal B-cell lymphoma and HL (14) . We examined the expression of c-Myc, a main member of the Myc family in HDLM-2 cells, and noted a dramatic suppression after ruxolitinib treatment and, moreover, complete elimination with the three-reagent combinations (Fig.  4B) . These results confirmed that the inhibition of JAK/STAT signaling pathway with ruxolitinib affected the relative abundance and functional activity of Bcl-2 family members in response to Navitoclax-induced apoptosis and BV-induced cell toxicity.
BV Combined with Ruxolitinib, Navitoclax, or Both Led to an Apparent Cure of the HDLM-2 HL. Constitutive activation of JAK/STAT was manifested in HDLM-2 cells that express CD30 on their cell surfaces. We investigated the therapeutic efficacy of all possible combination regimens of ruxolitinib, Navitoclax, and BV in the HDLM-2 xenograft mouse model of human HL. Therapy was initiated when the average volume of s.c. tumors reached 100 mm 3 . HDLM-2 tumor-bearing mice were randomly divided into eight groups with comparable mean tumor volumes, and the experiment was terminated on day 250 after tumor cell inoculation. Treatment with either ruxolitinib or Navitoclax significantly inhibited the tumor growth as demonstrated by a reduction in tumor volume compared with controls ( Fig. 5A ; P < 0.01). Although the treatment involving ruxolitinib combined with Navitoclax yielded a greater therapeutic efficacy (P < 0.01) compared with either single agent, HDLM-2 tumors manifested accelerate growth when the treatments were terminated (Fig. 5A) . Treatment with BV dramatically inhibited tumor growth compared with the other two single-agent groups (P < 0.01). The BV group appeared tumor-free 5 wk after starting therapy (Fig. 5A) . However, tumor recurred in the mice of the BV-treated group 1 mo after tumor initially became undetectable. Treatments with BV combined the other two individual agents or all three together yielded a greater reduction in tumor volume than observed with BV alone. After 4 wk of therapy, the double-combination groups yielded a complete response that was maintained for the 250 d of observation (Fig. 5A) . After 10 d of therapy, the triple group yielded a complete response, and the mice remained tumor-free over the same time period.
Meanwhile, the surrogate tumor marker serum levels of soluble IL-2R alpha (sIL-2Rα) paralleled the clinical observations and aided in prediction of tumor recurrence. Compared with the control group, there were reductions of sIL-2Rα in both ruxolitinib and Navitoclax individual groups (P < 0.05 compared with control group) at 6 wk, but the reductions were no longer evident at 8 or 13 wk after tumor inoculation. There were greater reductions in sIL-2Rα with the combination group (P < 0.01) compared with single-agent treatment groups. Furthermore, very low but detectable levels in the BV group of sIL-2Rα (range 23-2,121 pg/mL) were present at 6 and 8 wk (P < 0.001), which rose by the 13-wk time point. In contrast to other groups, the sIL-2Rα levels in all combination groups involving BV with ruxolitinib and/or Navitoclax became and remained undetectable (compared with BV, P < 0.05; Fig. 5 B-D) . (Fig. 6A) . At 13 wk after inoculation of tumor cells, the mice treated with BV alone had a tumor recurrence with a measurable tumor mass compared with combination treatment groups with BV (Fig. 6B ). All combinationtreatment groups with BV manifested a sustained complete response in the tumor-bearing mice that was confirmed by survival of all mice for the total 250-d period of observation (combination vs. BV, P < 0.0001; Fig. 6A ). The therapeutic study was repeated with four groups of HDLM-2 tumor-bearing mice that included a control group, ruxonitinib-treated group, BV-treated group, and ruxonitinib plus BV-treated group, respectively. The results of the second study were comparable to those observed in the initial study (Fig. S8 ).
Discussion
Recently, there have been major advances in the treatment of HL relapsing after autologous bone marrow transplantation. Amplifications of the 9p24 location in HL caused high amounts of JAK2 and PD-L1 to be made in HL cells (34) . Taking advantage of this observation, anti-PD1 immunotherapy has been associated with remissions in refractory and relapsed HL (35) . In particular the anti-PD1 monoclonal antibody blocked the immune privilege that PD-L1 confers on HL cells, allowing T cells to kill malignant RS cells (35) . Furthermore, the FDA has approved the anti-CD30 toxin conjugate BV for the treatment of relapsed HL after failure of autologous stem cell transplantation. There were 32% CRs, with a median response of 6.7 mo. Nevertheless, because such single-agent therapy is not curative, there is a need for combination therapy involving BV. In parallel with these clinical observations using a murine xenograft model with the HDLM-2 HL cell line, in the present study we examined the action of BV alone and in selected drug combinations. Single-agent therapy with BV led to an initial marked tumor response, but did not cure the disease, with recurrences developing in each of the 13 mice studied. Therefore, we evaluated the administration of the FDA-approved JAK1/2 inhibitor ruxolitinib, with BV in this model. The scientific basis for the addition of ruxolitinib was that in HL, there is a frequent selective 9p24.1 amplification inducing augmented expression of JAK2-a target of ruxolitinib. Furthermore, the expression of IL-6 and -13 leading to constitutive activation of JAK/STAT signaling has been observed in HRS cell lines. In our two preclinical trials, in the HDLM-2 model, the addition of ruxolitinib to BV led to the long-term persistent elimination of the established HL xenografts. It should be noted that single agent ruxolitinib profoundly inhibited the proliferation of two (L1236 and HDLM-2) of the six HL lines studied. This finding suggests that the development of biomarkers would be of value to differentiate between HL tumors responsive to ruxolitinib from tumors that do not respond. In terms of such biomarkers L1236 and HDLM-2 produced IL-6, -6R, and -13; manifested phosphorylation of STAT3, STAT5, and STAT6; and, as analyzed by Taqman PCR, had evidence for increased JAK2 via chromosome 9p24.1 amplification (Fig. S2) . Although the combination of BV and ruxolitinib was sufficient in the HDLM-2 murine model, in refractory and relapsed HL, additional agents would probably be required. To further develop a combination therapy, we evaluated the three-drug combination of BV, ruxolitinib, and the Bcl-2/Bcl-xL inhibitor Navitoclax. Previously we demonstrated that the combination of ruxolitinib and Navitoclax showed additivity/synergy when evaluated in a murine model of ATL. Furthermore, this combination showed additivity with the HL cell line HDLM-2. A number of observations support this combination. When the selective JAK1/2 inhibitor ruxolitinib was examined in a high-throughput matrix screen combined with 1,912 potential therapeutic agents with the cell line HDLM-2, and the Bcl-2/Bcl-xL inhibitor, Navitoclax, was identified as a strong candidate for multicomponent therapy because the drug combination blocked the proliferation and induced cell death of this HL cell line. The Bcl-2 specific inhibitor ABT-199 showed markedly less activity than Navitoclax in the inhibition of the proliferation of both ATL and HL cell lines. In prior studies, the combination of ruxolitinib and Navitoclax induced enhanced permeabilization of the mitochondrial membrane in IL-2-dependent ATL cell lines. Furthermore, in both ATL and HL cell lines, the combination of ruxolitinib and Navitoclax induced caspases-3/-7 activation, which resulted in cleavage of PARP and Mcl-1from its 40-kDa antiapoptotic to a 24-kDa proapoptotic form. Critically, the combination of ruxolitinib and Navitoclax inhibited tumor growth and resulted in prolonged survival of HL tumor-bearing mice. Furthermore, when used in combination with BV, it led to the persistent elimination of tumors.
In summary, the present study demonstrated that the combination of BV with ruxolitinib and Navitoclax or with ruxolitinib alone provided additive/synergistic activity in a mouse-xenograft model of human HL. These findings provide support for a therapeutic trial for select patients with refractory or with relapsed HL that would follow autologous bone marrow transplantation and/or anti-PD1 therapy with a combination regimen that involves BV with ruxolitinib and Navitoclax or ruxolitinib alone.
Materials and Methods
Reagents and Cells. Ruxolitinib and Navitoclax were purchased from Selleckchem. BV was purchased from Seattle Genetics. Further details are included in SI Materials and Methods. 
